Abstracts tagged "methotrexate (MTX)"

Abstract Number: 352 • 2017 ACR/ARHP Annual Meeting
Psychometric Features of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients with Rheumatoid Arthritis (RA): Preliminary Results from an Online Patient Community
Elodie de Bock¹, Corrado Bernasconi², Tan P. Pham¹, Ana Maria Rodriguez³, Khaled Sarsour⁴, J. Michael Nebesky² and Christine de la Loge¹, ¹Mapi, Lyon, France, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Patients Like Me (PLM), Cambridge, MA, ⁴Genentech, South San Francisco, CA
Background/Purpose: F. Hoffmann-La Roche Ltd. and Mapi collaborated to develop a medication adherence measure among RA patients taking MTX—the Methotrexate Experience Questionnaire (MEQ). The MEQ…
Abstract Number: 2449 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy with Tumor Necrosis Factor Inhibitors (TNFi) in Combination with Varying Doses of Methotrexate (MTX) in Patients with Rheumatoid Arthritis
Leslie R Harrold¹, George W. Reed¹, Jennie Best², Steve Zlotnick², Gioia Persuitte³ and Joel Kremer⁴, ¹University of Massachusetts Medical School, Worcester, MA, ²Genentech, Inc., South San Francisco, CA, ³Corrona, LLC, Southborough, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Clinical studies have shown that the efficacy of TCZ monotherapy (TCZ mono) is superior to that of TNFi monotherapy and comparable to that of…
Abstract Number: 363 • 2017 ACR/ARHP Annual Meeting
Work Productivity Benefit in Patients with Rheumatoid Arthritis Initiating Etanercept in the United States
Mahdi Gharaibeh¹, Bradley S. Stolshek², Alex Mutebi³, Amy M. Sainski-Nguyen⁴, David Collier⁵ and Emily Durden⁴, ¹Amgen Inc., Thousand Oaks, CA, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Thousand Oaks, CA, ⁴Truven Health Analytics, Ann Arbor, MI, ⁵Amgen, Inc, Terni, Italy
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can progress to joint destruction, functional impairment and disability that can lead to work productivity…
Abstract Number: 2453 • 2017 ACR/ARHP Annual Meeting
Methotrexate Discontinuation from Combination Therapy with Adalimumab Is Not Associated with Inferior Outcomes at 6 Months
Dimitrios A. Pappas¹, Chitra Karki¹, Ying Shan¹, Jessica L. Suboticki², Jenny Griffith³ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate is frequently administered in combination with biologics for the therapy of Rheumatoid Arthritis (RA) as it leads to superior outcomes compared to biologic…
Abstract Number: 446 • 2017 ACR/ARHP Annual Meeting
Methotrexate Use and Fatigue in Rheumatoid Arthritis Patients: Results from a National Patient Registry
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX), a synthetic disease-modifying antirheumatic drug (DMARD), is the most commonly used medication for rheumatoid arthritis (RA). Considerable variations between patients taking MTX…
Abstract Number: 2458 • 2017 ACR/ARHP Annual Meeting
Tocilizumab Inhibits Progression of Erosive Joint Damage in Early Rheumatoid Arthritis More Effectively Than Step-up Methotrexate Therapy
Xavier M Teitsma¹, Johannes WG Jacobs¹, Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Jacob M. van Laar⁵, Floris PJ Lafeber⁵ and Johannes W.J. Bijlsma², ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: In early rheumatoid arthritis (RA), starting therapy as soon as possible is important to reduce disease activity and preserve the joints. With application of…
Abstract Number: 493 • 2017 ACR/ARHP Annual Meeting
Methotrexate Is an Antibacterial Drug Metabolized By Human Gut Bacteria
Renuka R. Nayak¹, Kye Stapleton-Gray², Colleen O'Loughlin³, Michael Fischbach⁴ and Peter J. Turnbaugh⁵, ¹Department of Medicine, Division of Rheumatology, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Carnegie Mellon University, Pittsburgh, PA, ³University of California, San Francisco, San Francisco, CA, ⁴Department of Bioengineering and Therapeutic Sciences,, University of California, San Francisco, San Francisco, CA, ⁵Microbiology and Immunology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology causing inflammation and irreversible damage in joints and other organs. Methotrexate (MTX) is first-line…
Abstract Number: 2460 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jennie Best⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) often receive methotrexate (MTX) in combination with biologics; however, MTX may be discontinued due to intolerance or to reduce…
Abstract Number: 615 • 2017 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib By Background Methotrexate Dose in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Pooled Data from 2 Phase 3 Trials
Alan J. Kivitz¹, Oliver FitzGerald², Peter Nash³, Shirley Pang⁴, Valderilio F Azevedo⁵, Elizabeth Kudlacz⁶, Cunshan Wang⁶, Daniela Graham⁶ and Liza Takiya⁷, ¹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ²Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ³Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ⁴St. Jude Medical Center, Fullerton, CA, ⁵Universidade Federal do Paraná, Curitiba, Brazil, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). The efficacy of tofacitinib has been evaluated in 2 Phase 3…
Abstract Number: 2465 • 2017 ACR/ARHP Annual Meeting
Association between Methotrexate Use and Effects of Treatment with a Second Biologic Agent in Rheumatoid Arthritis: A Multiple Imputation Approach
Yoshikazu Ogawa¹, Nobunori Takahashi², Naoki Ishiguro² and Toshihisa Kojima², ¹Sakashita Hospital, Nakatsugawa, Japan, ²Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Methotrexate (MTX) is recommended and widely prescribed as the first-line, evidence-based therapy for rheumatoid arthritis (RA) patients. Previous studies have demonstrated a significant effect…
Abstract Number: 804 • 2017 ACR/ARHP Annual Meeting
The Efficacy and Safety of the Anti-IL-6 Receptor Antibody Tocilizumab for Polymyalgia Rheumatica Patients with Resistance or Intolerance to Glucocorticoids and Methotrexate
Manami Hirata¹, Akiko Ueno², kazuyuki fujita², Nobuyuki Shibutou² and Masahiro Yamamura³, ¹Center for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ²Centor for Rheumatology, Okayama Saiseikai General Hospital, Okayama, Japan, ³Okayama Saiseikai General Hospital, Okayama, Japan
Background/Purpose: Some patients show inadequate responses to initial glucocorticoids (GC) doses or relapses during GC tapering and develop side effects of GCs. The 2015 EULAR/ACR…
Abstract Number: 2962 • 2017 ACR/ARHP Annual Meeting
MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Charles Peterfy¹, Joel Kremer², William F C Rigby³, Nora Singer⁴, Christine Birchwood⁵, Darcy Gill⁵, William Reiss⁵, Jinglan Pei⁵ and Margaret Michalska⁵, ¹Spire Sciences, Inc., Boca Raton, FL, ²Albany Medical College, Albany, NY, ³Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Genentech, Inc., South San Francisco, CA
Background/Purpose: Although previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of rheumatoid arthritis (RA),1,2 changes in active…
Abstract Number: 49 • 2017 Pediatric Rheumatology Symposium
Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis
Charlene Hopper¹, Sarah Khan², Jacqueline Mancini² and Janet Rennick^3,4, ¹Rheumatology, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, ²Ingram School of Nursing, McGill University, Montreal, QC, Canada, ³Nursing, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, ⁴Ingram School of Nursing and Department of Pediatrics, McGill University, Montreal, QC, Canada
Background/Purpose: Methotrexate (MTX) remains an effective and commonly used disease modifying anti-rheumatic drug (DMARD) for the treatment of Juvenile Idiopathic Arthritis (JIA). Approximately half of the children taking MTX will…
Abstract Number: 12 • 2016 ACR/ARHP Annual Meeting
Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)
Soledad Retamozo¹, Maria Jezabel Haye Salinas², Juan Pablo Pirola³, Diego Baenas², Ana C. Alvarez⁴, Veronica Saurit³, Alejandro Alvarellos⁵, Christian A. Waimann⁶, Gustavo Citera^7,8, Fernando Dal Pra⁹, Celeste Orozco⁹, Federico Ceccato¹⁰, Sergio Paira¹⁰, MV Martire¹¹, G Crespo Amaya¹¹, Anastasia Secco¹¹, M Mamani¹¹, Javier Rosa¹², Enrique Soriano¹², Josefina Marcos¹³, Mercedes Argentina García¹⁴, Carolina Costi¹⁵, María M Zalazar¹⁶, Alejandro Martinez Muñoz¹⁶, Oscar Luis Rillo¹⁷, Horacio Berman¹⁸, Alberto Berman¹⁸, Francisco Colombres¹⁸, Edson Javier Velozo¹⁹, Vicente Ricardo Juarez²⁰, M Crespo²⁰, A Quinteros²¹, M Leal²¹, G Salvatierra²², Monica Sacnún²³, R Quintana²³, M Abdala²⁴ and Francisco Caeiro²⁵, ¹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ²Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ³Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁴Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina, ⁵Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ⁶Escuela Superior de Ciencias de la Salud, UNICEN., Olavarria,, Argentina, ⁷Rheumatology, Instituto de Rehabilitacion Psicofisica - Fundacion Reumatologica Argentina Dr. Osvaldo Garcia-Morteo, Buenos Aires, Argentina, ⁸Rheumatology, CONAART - IREP, Buenos Aires, Argentina, ⁹Instituto De Rehabilitación Psicofísica, Argentina, CABA, Argentina, ¹⁰Hospital Dr José María Cullen, Santa Fe, Argentina, ¹¹Hospital Bernardino Rivadavia, CABA, Argentina, ¹²Hospital Italiano De Buenos Aires, CABA, Argentina, ¹³Hospital San Martin, La Plata, Argentina, ¹⁴Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ¹⁵Hospital San Martín, LaPlata, Argentina, ¹⁶Hospital Pirovano, CABA, Argentina, ¹⁷Rheumatology Department, Hospital General de Agudos “Dr. Ignacio Pirovano”, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁸Centro Médico Privado De Reumatología (Tucumán), Tucumán, Argentina, ¹⁹Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, ²⁰Hospital Señor Del Milagro, Salta, Argentina, ²¹Centro Integral De Reumatología, Tucumán, Argentina, ²²Instituto Provincial De Rehabilitación Integral, Santiago del Estero, Argentina, ²³Hospital Provincial De Rosario, Rosario, Argentina, ²⁴Hospital Provincial Del Centenario, Rosario, Argentina, ²⁵Rheumatology, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina
Background/Purpose: To analyze clinical remission in patients with early RA and undifferentiated arthritis (UA) during the first 2 years of treatment using methotrexate (MTX) and…
Abstract Number: 2522 • 2016 ACR/ARHP Annual Meeting
Pharmacomicrobiomics of Methotrexate: Baseline Intestinal Microbiota Correlates with Therapeutic Response
Carles Ubeda¹, Shahla Abdollahi-Roodsaz², Steven B. Abramson³ and Jose U. Scher⁴, ¹Institute for Research in Public Health, Valencia, Spain, ²Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research, NYU School of Medicine and NYU Hospital for Joint Diseases, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Despite significant advances in the therapeutics of inflammatory arthritides, methotrexate (MTX) remains the mainstay of treatment for rheumatoid arthritis (RA) and related conditions worldwide.…

« Previous Page
1
…
4
5
6
7
8
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].